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Summary
Vitamin supplements have been proposed for children with Down syndrome (DS) with claims of
improving cognitive abilities, or immune or thyroid function. Several studies have shown
decreased levels of zinc in this population. Because children with DS have a 50-fold increased risk
of developing acute leukemia during the first 5 years of life, we explored the relation between
child vitamin and herbal supplement use and the risk for leukemia in a case-control study. During
the period 1997–2002, we enrolled 158 children with DS aged 0–18 years that were diagnosed
with acute lymphoblastic leukemia (ALL) (n=97) or acute myeloid leukemia (AML) (n=61) at
participating COG institutions. We enrolled 173 DS children without leukemia (controls), selected
from the cases’ primary care clinic and frequency matched on age. Data were collected via
telephone interviews with mothers of the index child regarding use of multivitamins, zinc, vitamin
C, iron, and herbal supplements, including age at first use, frequency and duration. Among
controls, 57% reported regular multivitamin use (≥ 3 times/week for ≥ 3 months) compared with
48% of ALL cases and 61% of AML cases. We found no evidence of an association between
child’s regular multivitamin use and ALL or AML (adjusted odds ratios (ORs)=0.94 [95%
confidence interval 0.52, 1.70] and 1.90 [0.73, 4.91], respectively. There was a suggestion of an
increased risk for AML associated with regular multivitamin use during the first year of life or for
an extended duration (ORs = 2.38 [0.94, 5.76] and 2.59 [1.02, 6.59], respectively). Despite being
the largest study of DS-leukemia, our sample size was small, resulting in imprecise effect
estimates. Future research should include larger sample sizes as well as a full assessment of diet
including vitamin supplementation to adequately examine the relation between nutritional status
and childhood leukemia.
Introduction
Children with Down syndrome (DS) have an increased risk for congenital heart defects,
thyroid dysfunction, gastrointestinal abnormalities, and immune system deficiencies
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compared to children without DS.1–3 For many decades, vitamin and herbal supplements, in
various doses and formulas, have been recommended for children with DS with claims of
improving cognitive abilities or immune function or of alleviating thyroid or gastrointestinal
dysfunction. Additionally, some studies have reported that children with DS are more prone
to vitamin and mineral deficiencies.4 In particular, several studies have shown serum or
plasma levels of zinc to be below normal in this population.5–7 Zinc deficiency, even at mild
levels, may contribute to impairment of immune function.8, 9 Consequently, a large
proportion of children with DS are given supplements, often within the first couple of years
of life.
Children with DS below the age of five have a 40-fold increased risk of ALL and a 150-fold
increased risk of myeloid leukemia.10 The role of trisomy 21 in DS leukemogenesis remains
unknown. Since leukemia is much more common in this population, risk factors may be
identified more readily. Investigation of acute leukemia in a population of children with DS
may help elucidate the etiology of this disease, not only for these children, but also for
children without DS. Since children with DS are targeted for vitamin supplement use,
especially at an early age, and few risk factors have been identified for the increased risk of
leukemia in this population, we performed an exploratory analysis to examine the




Details of this study have been previously published.11, 12 Briefly, the cases were children
with DS who were diagnosed with acute leukemia before age 20 between 1997 and 2002.
They were identified through registration files of the Children’s Oncology Group (COG),
which consists of over 200 institutions. An estimated 94% of leukemia patients under age 15
and 73% under age 20 are treated at one of the COG institutions.13, 14 Patients were eligible
for the study if they resided in North America at the time of diagnosis, had an English
speaking biological mother, and had a telephone in the home. Maternal interviews were
successfully completed for 158 out of 210 leukemia patients identified through 116 COG
institutions. Reasons for non-interview included maternal refusal (17%), physician refusal
(5%), and inability to locate the mother (3%).
Controls were identified through a roster of children with DS with no history of leukemia,
provided by the primary care physician who treated one of the cases. Potential controls were
randomly selected from the rosters and frequency matched to cases on age at leukemia
diagnosis (<1, 1–3, 4–6, 7–10, 11–14, and 15–18 years). Of the 726 potential controls
provided by the primary care clinics, 329 were randomly selected based on date of birth. The
clinics were unable to provide contact information (names and addresses) for 114 children
due to inability to contact the family (n=46), refusal of clinic’s request by the family (n=19),
ineligibility (n=18), refusal to contact the family (n=8), or other unreported reasons (n=23).
Of the 215 children for whom the clinics provided names and addresses, telephone
interviews were successfully completed for 173 mothers (80.5%). Reasons for non-interview
include maternal refusal (n=24), ineligibility (n=9), or inability to schedule an interview
(n=9). The Institutional Review Boards of the University of Minnesota and participating
COG institutions have approved this study.
Data Collection
A structured, computer-assisted telephone questionnaire was administered by a trained
interviewer to biological mothers of both cases and controls. The interview consisted of
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questions pertaining to sociodemographic factors, pregnancy history, as well as maternal and
child medical history. In order to provide a similar time frame for childhood exposures
among cases and controls, a reference date was assigned to each child prior to the interview.
For cases, the reference date was six months prior to leukemia diagnosis. For controls, the
reference date was a randomly selected day within 12 months of the child’s birthday during
the year of the frequency match. Mothers were asked about the index child’s use of vitamin
or herbal supplements from birth until the reference age. Information was collected
specifically for multivitamins, zinc, vitamin C, and iron supplements including age at first
use, frequency and duration. A separate question assessed use of holistic or herbal
treatments and/or supplements, allowing the mother to specify up to 3 different kinds.
Statistical analyses
The vitamin/herbal supplement questions were only asked of mothers whose index child had
a reference age greater than one to allow for a latency period, thus 21 cases and 54 controls
were excluded from the current analysis resulting in 137 cases (96 ALL; 41 AML) and 118
controls. Since there were varied responses to the question on herbal supplements, small
numbers precluded assessment of individual supplements or categories of supplements (e.g.,
digestive aids, immune or cognitive boosters). Additionally, use of megatherapy
supplements, such as NutriVene-D, was uncommon in our study participants and thus was
not evaluated separately. Secondary analyses were conducted to further explore
multivitamin use, since this was the most common type used. Herbal multi- or mega-vitamin
formula supplements (NutriVene-D daily supplement, Maxilife COQ-10, and megavitamin
not specified) were combined with regular multivitamins in these analyses. Regular
multivitamin use was defined as using a multivitamin three or more times per week for at
least three months. In order to assess the timing of the exposure, we estimated risks for
leukemia associated with multivitamin use during the first year of life (≥ 3 times per week
for ≥ 1 month). Additionally, we defined the post-natal window of exposure as the time
since birth until the reference age. To account for reference age while evaluating duration of
supplement use, we created a variable indicating whether the child used a multivitamin for
more or less than one-half of the time during the window of exposure (duration ratio = (stop
date − start date)/reference age).
The association between vitamin use among children with DS and acute leukemia was
estimated using unconditional logistic regression. The following variables were examined as
potential confounders: maternal sociodemographic factors (age, education, ethnicity, and
household income), maternal vitamin use before and during index pregnancy, breast feeding,
and child characteristics (gender, birthweight, birth order, and reference age). Covariates
were only retained in the final multivariable regression model if they modified the risk
estimate by 10% or greater. Multivariable-adjusted analyses were performed to estimate the
odds ratios (OR) and 95% confidence intervals (95% CI). All statistical tests were 2-sided.
Analyses were conducted for acute leukemia combined as well as stratified on leukemia
subtype (ALL and AML).
Results
In this case-control study of 137 DS-leukemia cases and 118 DS-controls, 56.9% of cases
and 57.6% of controls were reported to have used a multivitamin compared with 30%–54%
of US children.15–19 Among the multivitamin users, the majority started taking
multivitamins during their first year of life (54% controls, 69% cases) and took one or more
a day (90% controls, 93% cases). Only 10.9% of controls and 7.3% of cases were using a
non-multivitamin herbal supplement, such as Echinacea, Naturnicum, Silver, Ginko balboa,
etc.
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Selected maternal and child characteristics are presented in Table 1. Compared with control
mothers, cases mothers were more likely to be older (≥ 35) at the index child’s birth, but less
likely to be Caucasian or to have completed education beyond high school. Mothers of ALL
cases were less likely to have initiated multivitamin use before knowledge of index
pregnancy. AML cases weighed more at birth compared with controls. While the mean age
of ALL cases and controls was similar (5.9 vs. 6.3 years), the ALL cases were more likely to
be in the 2–5 year age group compared with controls. The AML cases were substantially
more likely to be in the less than 2 year age group compared with controls (73% vs. 19%).
There was no evidence for an association between any multivitamin use or regular
multivitamin use and acute leukemia, either ALL or AML (Table 2). The ORs for regular
use of multivitamins were 0.94 [95% CI 0.52, 1.70] for ALL and 1.90 [0.73, 4.91] for AML.
Similarly, for the individual vitamins assessed in the interview, zinc, iron, and vitamin C,
there was no statistically significant association with leukemia; however, the exposure
prevalence was very low, thus resulting in wide confidence intervals. There were no
appreciable changes in the estimates when the analyses were repeated for AML cases
including only those controls less than five years of age.
Additional analyses were performed to account for timing and duration of childhood
multivitamin use. ORs associated with regular multivitamin use during the first year of life
(≥3 times per week for ≥1 month) were 1.43 [0.75, 2.71] for ALL and 2.38 [0.94, 5.76] for
AML. When we examined the proportion of time during the post-natal exposure window
(birth until reference age) that the child used a multivitamin supplement, we found no
evidence for an association with ALL. Compared to children who did not take a
multivitamin supplement, the ORs for ALL were 1.43 [0.74, 2.77] for children whose
supplement use occurred for less than one-half the time and 1.06 [0.50, 2.23] for use
occurring more than one-half of the time. However, there was an increased risk for AML
among children who used a multivitamin for more than one-half of the duration of their
post-natal exposure window (OR=2.59 [1.02, 6.59]) compared with non-users. The
increased risk for AML was still elevated but somewhat attenuated when restricted to
controls with reference age ≤ 5 years for both timing and duration of multivitamin use.
When analyses were restricted to cases for whom controls were selected from the same
clinic, there were no substantial differences with the possible exception of an increased risk
of acute leukemia associated with any multivitamin use (OR = 2.73, [95% CI 1.19, 6.27]).
Discussion
The majority of studies that have examined vitamins and risk for childhood leukemia have
focused on maternal use around the time of pregnancy, with several studies reporting a
decreased risk of childhood ALL,20, 21 including our current study.12 Two of these studies
conducted in children without DS found a 30% and 60% decreased risk of ALL associated
with maternal use of vitamins (type not specified)21 and folate supplementation with or
without iron20, respectively. In a previous analysis of the current case-control study, we
observed a reduced risk of ALL (OR 0.51, [95% CI 0.30, 0.89]) but not AML (OR 0.92,
[95% CI 0.48, 1.76]) in children with DS whose mothers took vitamin supplements during
the periconceptional period.12 Few studies have specifically evaluated the association
between post-natal vitamin supplementation and subsequent development of childhood
leukemia. Ours is the first to study this association among children with DS.
Several studies have evaluated child diet in relation to leukemia (excluding children with
DS), focusing on N-nitroso precursors found in some foods like cured meats that are thought
to lead to carcinogen formation if not blocked.22–24 Only two of these studies assessed child
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vitamin use in addition to diet. In a case-control study, there was no significant association
between childhood acute leukemia (mostly ALL) and use of vitamins during the first 2 years
of life, with or without adjustment for child’s diet (OR=0.70, [95% CI 0.42, 1.18]; OR=0.88,
[95% CI 0.59, 1.31], respectively).22 In an earlier study, child vitamin use was evaluated as
a confounder and effect modifier of meat consumption, with no mention of a risk estimate
for vitamin intake alone.24 These studies only included assessment of certain foods and food
groups, thus childhood leukemia research to date has not included in-depth assessment of
child nutritional status.
While there is some evidence that vitamin supplementation may reduce the risk of selected
adult malignancies, there are inconsistencies in the literature. In general, randomized clinical
trials have not shown a significant protective effect, however, most trials have either
included only high risk populations, examined a limited number of micronutrients, involved
a limited duration of treatment or follow-up, or used high doses that far exceed the current
recommended amount.25, 26 The results among observational studies are inconclusive as
well.26 Nonetheless, there is biologic plausibility for an effect of vitamin supplementation
on cancer risk, although where it occurs along the continuum from protective to harmful is
not yet known. Inadequate intake of important micronutrients may contribute to DNA
damage, in the form of single or double stranded breaks or oxidative lesions, which may in
turn contribute to cancer development.8, 27 Additionally, undernutrition, either through
insufficient intake of macro-and/or micro-nutrients may contribute to impairment of immune
functioning.9, 28 On the other hand, supplement use among individuals at high risk of
malignancy may promote carcinogenesis through either the proliferation or inhibition of
apoptosis of mutated cells. In two large chemoprevention trials, there was an increased risk
of incident lung cancer among heavy smokers and workers exposed to asbestos who
received beta-carotene supplements compared with those who received a placebo.29, 30
In our study, we found the suggestion of a possible increased risk for AML, however, our
sample size was small and the observed elevated ORs may have resulted from multiple
comparisons. AML in children with DS is different demographically and biologically than
AML in children without DS. Not only is AML more common among children with DS
(about half of the leukemias),31, 32 it also presents at an earlier age (median = 2 years in DS
vs. 8 years in non-DS children).33 The most common subtype of AML in children with DS
is acute megakaryoblastic leukemia (AMKL), which is rare in non-DS children. More
importantly, DS-AMKL is characterized by mutations in the hematopoietic transcription
factor GATA1 and has a more favorable response to treatment compared with non-DS-
AMKL.34. Infants with DS are predisposed to transient myeloproliferative disorder (TMD),
which usually regresses spontaneously. However, 20–30% of TMD patients subsequently
develop AMKL within the first four years of life.35 Interestingly, mutations in GATA1 are
found in TMD blasts and AMKL blasts, but are not found in children without DS, except in
cases with acquired trisomy 21 in their leukemic cells.31 There is evidence that GATA1
mutations, like TMD, can occur during fetal development. (reviewed in 31) Since neither DS
nor the GATA1 mutation are sufficient for development of AML, it is likely that postnatal
events play a role.
While some studies have reported certain vitamin and mineral deficiencies in children with
DS, many had major methodological problems such as small sample size, lack of controls,
or short duration of follow-up.3, 36 Consequently, there is no clear and consistent evidence to
support vitamin supplementation in children with DS. However, the importance of adequate
micronutrient intake on physiological, immunologic, or developmental processes for all
children, regardless of susceptibility to micronutrient deficiencies, is undisputed.
Blair et al. Page 5













Despite being the largest case-control study of DS-leukemia, our sample size was small and
the exposure prevalence of specific types of vitamins was low, thus limiting power to detect
small risks. Nevertheless, for regular multivitamin use, with an exposure rate of 57% in
controls, at an alpha level of 0.05, we had 85% power to detect an increased risk of 1.92 or a
decreased risk of 0.54. Thus, if there was a strong positive (2-fold or higher) or negative (0.5
or lower) association between regular multivitamin use and acute leukemia, we would have
had sufficient power to detect such an association. While our data lacked information on
vitamin dose, we did have information on frequency and duration of use. An additional
limitation to the current analysis is the lack of dietary data for the case and control subjects,
which would be needed to conduct a full assessment of nutrient intake.
There is a possibility of recall bias, as childhood use of vitamin supplements was reported
by the mother. However, the high prevalence of multivitamin use in children during the past
decade or two, especially in this population, might minimize the potential for substantial
bias. As with most case-control studies, there is a potential for selection bias, particularly
among controls. It is unlikely that our cases differed much from the population of children
with DS since a child with DS diagnosed with leukemia in the United States would likely be
referred to and treated at a COG institution, which treat 94% of all leukemia cases.13, 14
Since the focus for this case-control study concerned maternal periconceptional exposures,
only biological mothers were included in the study. Only five cases and nine controls were
excluded, thus minimizing any potential selection bias due to this inclusion criterion. The
potential for selection bias in this study is strongest for controls as there is no population-
based national registry for DS. Thirty-one percent of clinics refused or were unable to
provide rosters of children with DS and contact information was not provided for 35% of the
children selected as potential controls. However, among the controls referred to the study,
the participation rate was high (80%). Moreover, restricting analyses to only case children
who had a control from the same clinic did not notably change the results.
Our results do not support a strong association between childhood vitamin use and risk of
ALL among children with DS. In contrast, there is a suggestion of an increased risk of
AML, particularly among those children who begin taking vitamins during their first year of
life or take them for a long duration. Additional studies with larger sample sizes are needed
to confirm these results. Prior studies have investigated the effect of maternal or child diet
on childhood acute leukemia, though most involved a limited dietary questionnaire and few
included vitamin supplementation. Additionally, the majority of studies on vitamin
supplementation have examined maternal use during the periconceptional period. In order to
adequately examine the association between nutritional status and childhood leukemia risk,
future studies should include a complete assessment of both maternal and child diet
including vitamin supplementation.
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